The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer (BC) is low, and the role of some of these genes in BC predisposition and pathogenesis is conflicting. In this study, 5589 consecutive BC index patients negative for pathogenic BRCA1/2 mutations and 2189 female controls were screened for germ line mutations in eight cancer predisposition genes (ATM, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and TP53). All patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germ line testing. The highest mutation prevalence was observed in the CHEK2 gene (2.5%), followed by ATM (1.5%) and PALB2 (1.2%). The mutation prevalence in each of the remaining genes w...
PURPOSE: Recent advances in DNA sequencing have led to the development of breast cancer susceptibili...
Recently, BRCA1 germline mutations were found in a high proportion (14–34%) of patients with triple-...
Background: Germline genetic testing with hereditary cancer gene panels can identify women at increa...
The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer ...
The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer ...
BackgroundBreast cancer has a significant heritable basis, of which ∼60% remains unexplained. Testin...
Abstract Background Breast cancer is the most common cancer in women. 12–15% of all tumors are tripl...
Introduction Two major high-penetrance breast cancer genes, BRCA1 and BRCA2, are responsible for ap...
Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast c...
Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BR...
<p>Four patients carried two different mutations:</p><p><sup>1</sup><i>BRCA1</i>-c.3700_3704delGTAAA...
The main focus of this German-wide multi-center study was to establish a BRCA1/2 mutation profile an...
Abstract Background Pathogenic BRCA1 founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% ...
Background: breast cancer has a significant heritable basis, of which ∼60% remains unexplained. Test...
Purpose: Gene panel sequencing is revolutionizing germline risk assessment for hereditary breast can...
PURPOSE: Recent advances in DNA sequencing have led to the development of breast cancer susceptibili...
Recently, BRCA1 germline mutations were found in a high proportion (14–34%) of patients with triple-...
Background: Germline genetic testing with hereditary cancer gene panels can identify women at increa...
The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer ...
The prevalence of germ line mutations in non-BRCA1/2 genes associated with hereditary breast cancer ...
BackgroundBreast cancer has a significant heritable basis, of which ∼60% remains unexplained. Testin...
Abstract Background Breast cancer is the most common cancer in women. 12–15% of all tumors are tripl...
Introduction Two major high-penetrance breast cancer genes, BRCA1 and BRCA2, are responsible for ap...
Patients with unilateral breast cancer (UBC) have an increased risk of developing bilateral breast c...
Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BR...
<p>Four patients carried two different mutations:</p><p><sup>1</sup><i>BRCA1</i>-c.3700_3704delGTAAA...
The main focus of this German-wide multi-center study was to establish a BRCA1/2 mutation profile an...
Abstract Background Pathogenic BRCA1 founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% ...
Background: breast cancer has a significant heritable basis, of which ∼60% remains unexplained. Test...
Purpose: Gene panel sequencing is revolutionizing germline risk assessment for hereditary breast can...
PURPOSE: Recent advances in DNA sequencing have led to the development of breast cancer susceptibili...
Recently, BRCA1 germline mutations were found in a high proportion (14–34%) of patients with triple-...
Background: Germline genetic testing with hereditary cancer gene panels can identify women at increa...